Repligen Corp vs Abbvie Inc.
RGEN vs ABBV — side-by-side comparison from reported financials. RGEN leads 1, ABBV leads 9 of 10 comparable metrics.
Repligen Corp
RGEN · Healthcare
$173.88+6.13%Mixed
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | RGEN | ABBV |
|---|---|---|
| Price | $173.88 | $276.43 |
| Market cap | $11.0B | $488B |
| Revenue (TTM) | $785M | $64.4B |
| Revenue growth | -2.7% | +1.8% |
| Net margin | 5.3% | 9.8% |
| Free cash flow | $112M | $18.2B |
| Net cash (debt) | $225M | ($56.2B) |
| 1-year price return | +16.8% | +19.8% |
| P/E | 265.8 | 77.4 |
| P/E vs own history (cheap-side %) | 2% | 23% |
| Dividend yield | — | 2.45% |
| Return on equity | 2% | 96% |
| Altman Z-score | — | 2.33 |
| CV checks passed | 7 of 10 | 9 of 10 |
| Employees | 2,000 | 57,000 |
Full résumé-style profiles: RGEN CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.